Abstract
Recently prednisolone has been used for the prevention of esophageal stenosis after endoscopic submucosal dissection (ESD). However, there is hesitation to use prednisolone in patients at risk when using steroids due to concomitant diseases such as diabetes mellitus and viral hepatitis. Budesonide is a steroid antedrug, which is a locally acting corticosteroid with a minimal systemic effect and high affinity. Therefore, budesonide might be safely used even for patients at risk with steroid usage. Thus far, we have used budesonide in 5 patients aiming to prevent esophageal stenosis after ESD. No stricture was observed in patients after removal of four fifths of the esophageal circumference. However, budesonide did not prevent strictures after removal of larger lesions. We are planning to evaluate this treatment further to validate its prophylactic effects.
